FindTrial
Sign In

To study and compare blood tests and cut specimens in patients of colorectal cancer.

To study the utility of serum lipids and CEA levels as novel markers in comparison to various histopathological parameters and Tumor Node Metastasis(TNM) staging in colorectal carcinoma. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/069979
Enrollment
68
Registered
2024-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified

Interventions

Intervention1: NIL: NA Control Intervention1: NIL: NA

Sponsors

Datta Meghe Institute of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Patients with a diagnosis confirmed through histopathological examination. •Patients with colorectal carcinoma that has originated de novo (without prior related history). •Primary cases of colorectal carcinoma with no history of previous treatment. •Patients who are not taking lipid-lowering medications.

Exclusion criteria

Exclusion criteria: •Patients who are taking lipid-lowering medications. •Patients who are receiving neoadjuvant chemotherapy for colorectal carcinoma. •Patients who have previously undergone surgical procedures for colorectal cancer before being enrolled in the study.

Design outcomes

Primary

MeasureTime frame
Serum lipid levels will be lower and CEA levels will be higher in comparison to various stages of colorectal carcinoma.Timepoint: Assessment will be done at 12 months.—

Secondary

MeasureTime frame
NILTimepoint: NA—

Countries

India

Contacts

Public ContactPravin Gadkari

Datta Meghe Institute of Higher Education and Research

prg835@gmail.com9373101668

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026